Crosstalk of Cancer Signaling Pathways by Cyclic Hexapeptides and Anthraquinones from .

The anticancer activities of and its constituents have been reported earlier, but their influence on the crosstalk of complex cancer-related signaling metabolic pathways (i.e., transcription factors; TF) has not yet been fully investigated. In this study, root extract was subjected to the cancer signaling assay based bioactivity-guided fractionation, which yielded the following compounds viz., three anthraquinones, namely alizarin (), purpurin (), and emodin (); two lignans, namely eudesmin () and compound ; and two cyclic hexapeptides, namely deoxybouvardin RA-V (), and a mixture of + (RA-XXI). The structures of the isolated compounds were determined by NMR spectroscopy and HRESIMS. The isolated compounds , , , and a mixture of + were tested against a panel of luciferase reporter genes that assesses the activity of a wide-range of cancer-related signaling pathways. In addition, reference anthraquinones viz., chrysophanol (), danthron (), quinizarin (), aloe-emodin (), and α-lapachone () were also tested. Among the tested compounds, the cyclic hexapeptide was found to be very active against several signaling pathways, notably Wnt, Myc, and Notch with IC values of 50, 75, and 93 ng/mL, respectively. Whereas, the anthraquinones exhibited very mild or no inhibition against these signaling pathways. Compound being the most active, we tested it for stability in simulated intestinal (SIF) and gastric fluids (SGF), since the stability in biological fluid is a key short-coming of cyclic hexapeptides. The anticancer activity of was found to remain unchanged before and after the treatment of simulated gastric/intestinal fluids, indicating that RA-V was stable. As a result, it could be bioavailable when orally used in therapeutics and possibly a drug candidate for cancer treatment. The mechanism for the preferential inhibition of these pathways and the possible crosstalk effect with other previously reported signaling pathways has been discussed.